US HB8624 | 2019-2020 | 116th Congress
Status
Spectrum: Moderate Partisan Bill (Republican 6-1)
Status: Introduced on October 16 2020 - 25% progression, died in committee
Action: 2020-10-16 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on October 16 2020 - 25% progression, died in committee
Action: 2020-10-16 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Allows the Centers for Medicare & Medicaid Services (CMS) to extend the duration of pass-through status (i.e., additional payment) for certain drugs and devices under the Medicare prospective payment system for hospital outpatient department services. Specifically, the CMS may extend the pass-through status of drugs and devices that received such status during the public health emergency relating to COVID-19 (i.e., coronavirus disease 2019) if their cost cannot be accurately calculated due to the effects of COVID-19. The bill's provisions apply to drugs and devices that had pass-through status during any portion of the public health emergency period, including those for which such status has already expired.
Title
Protecting Access to Innovation During COVID–19 Act
Sponsors
Rep. Brad Wenstrup [R-OH] | Rep. Sanford Bishop [D-GA] | Rep. Andy Harris [R-MD] | Rep. Kenny Marchant [R-TX] |
Rep. Mike Kelly [R-PA] | Rep. Brian Fitzpatrick [R-PA] | Rep. Richard Hudson [R-NC] |
History
Date | Chamber | Action |
---|---|---|
2020-10-16 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-10-16 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-10-16 | House | Introduced in House |
Same As/Similar To
HB14 (Related) 2020-11-02 - Referred to the Subcommittee on Railroads, Pipelines, and Hazardous Materials.
Subjects
Cardiovascular and respiratory health
Emergency medical services and trauma care
Health
Health technology, devices, supplies
Home and outpatient care
Hospital care
Infectious and parasitic diseases
Medicare
Prescription drugs
Emergency medical services and trauma care
Health
Health technology, devices, supplies
Home and outpatient care
Hospital care
Infectious and parasitic diseases
Medicare
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/8624/all-info |
Text | https://www.congress.gov/116/bills/hr8624/BILLS-116hr8624ih.pdf |